NCT05342220

Brief Summary

Remote ischemic preconditioning is one way to influence the success of therapy in cardiovascular patients. By means of remote ischemic preconditioning the incidence of atrial fibrillation after cardiac surgery was reduced by 54%. The investigators aim to investigate the effect of ischemic preconditioning in an easy-to-perform protocol with regard to the recurrence of atrial fibrillation after electrical cardioversion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P50-P75 for not_applicable atrial-fibrillation

Timeline
Completed

Started Apr 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2022

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

April 6, 2022

Completed
16 days until next milestone

First Posted

Study publicly available on registry

April 22, 2022

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

July 9, 2024

Status Verified

July 1, 2024

Enrollment Period

2 years

First QC Date

April 6, 2022

Last Update Submit

July 7, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of subjects with recurrence of atrial fibrillation 30 days after electrical cardioversion

    30 days

Secondary Outcomes (5)

  • Number of patients with short-term cardioversion success

    30 seconds

  • Minimum energy required for successful electrocardioversion (in Joule)

    30 days

  • Cumulative energy applied for successfull electrocardioversion (in Joule)

    30 days

  • Cumulative number of shocks delivered for successfull electrocardioversion

    30 days

  • Number of patients experiencing death from any cause, stroke /transient ischemic attack, relevant post-ECV arrhythmia and procedure-associated complications

    30 days

Study Arms (2)

Remote Ischemic Preconditioning

ACTIVE COMPARATOR

Remote ischemic preconditioining

Procedure: Remote ischemic preconditioning

Control

SHAM COMPARATOR

Sham preconditioning

Procedure: Sham preconditioning

Interventions

Remote ischemic preconditioning through inflation of a blood pressure cuff to pressure values \> 200mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)

Remote Ischemic Preconditioning

Inflation of a blood pressure cuff to pressure values \~ 10mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion

Control

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with paroxysmal or persistent atrial fibrillation who give written informed consent to participate in the study
  • Age \> 18 years
  • Consent capacity

You may not qualify if:

  • Age under 18 years
  • Pregnancy
  • Lack of consent capacity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Josefs-Hospital Wiesbaden

Wiesbaden, Hesse, 65189, Germany

Location

Related Publications (1)

  • Keim C, Wiedenmann L, Schubert T, Rothe M, Dobre BC, Kaess BM, Ehrlich JR, Boehmer AA. Remote Ischemic Preconditioning for Electrical Cardioversion of Atrial Fibrillation-the Prospective Randomized PRECON-AF Study. CJC Open. 2025 Mar 10;7(5):571-578. doi: 10.1016/j.cjco.2025.03.004. eCollection 2025 May.

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 6, 2022

First Posted

April 22, 2022

Study Start

April 1, 2022

Primary Completion

March 31, 2024

Study Completion

June 30, 2024

Last Updated

July 9, 2024

Record last verified: 2024-07

Locations